

Customer No.: 20462
Confirmation No.: 9816
Attorney Docket No. PU60782

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Jin, et al. Date: 27 February 2010
Serial No.: 10/598,750 Group Art Unit No.: 1624
Filed: 11 March 2005 Examiner: Unknown
For: Novel M3 Muscarinic Acetylcholine Receptor Antagonists

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

FILING OF AN INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §1.97(b)

Sir:

The attached list of citations on PTO Form 1449 is being submitted under the provisions of 37 CFR §1.56 and §1.97 for consideration by the United States Patent and Trademark Office, prior to the granting of this patent. Their inclusion herein should not, however, be construed as an admission that any particular cited document is effective prior art or that it discloses or renders obvious any aspect of the claimed invention. A copy of each cited document is enclosed, except U.S. Patent documents, and those references which are already part of the filewrapper. This statement is being filed within the time period specified in 37 CFR §1.97(b). No fee is required.

Respectfully submitted,



/

/

Dara L. Dinner
Attorney for Applicants
Registration No. 33,680

GLAXOSMITHKLINE
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-5017
Facsimile (610) 270-5090